perfluorooctanoic acid has been researched along with 2019 Novel Coronavirus Disease in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Andres, KL; Kleinschmidt, SE; Krisko, RM; Longnecker, MP; Olsen, GW; Porter, AK; Reusch, CN; Taiwo, OA | 1 |
Beitel, S; Britton, A; Burgess, JL; Caban-Martinez, AJ; Coleman, A; Dunnigan, K; Ellingson, KD; Fisher, JM; Fowlkes, AL; Fuller, S; Gaglani, M; Hegmann, KT; Hollister, J; Hunt, D; Khan, SM; Kuntz, JL; Lutrick, K; Mayo Lamberte, J; Meece, J; Naleway, AL; Nematollahi, A; Pavuk, M; Ramadan, FA; Rose, S; Schaefer Solle, N; Sprissler, R; Thiese, MS; Tyner, HL; Yoon, SK | 1 |
2 other study(ies) available for perfluorooctanoic acid and 2019 Novel Coronavirus Disease
Article | Year |
---|---|
Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances.
Topics: Alkanesulfonic Acids; Antibodies, Neutralizing; Antibody Formation; Caprylates; COVID-19; COVID-19 Vaccines; Environmental Pollutants; Fluorocarbons; Follow-Up Studies; Humans; Immunoglobulin G; Sulfonic Acids | 2022 |
Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies.
Topics: Alkanesulfonic Acids; Antibodies; COVID-19; COVID-19 Vaccines; Environmental Pollutants; Fluorocarbons; Humans; SARS-CoV-2; United States | 2023 |